A Phase 2 interventional study of INCB054707 and Placebo in Hidradenitis Suppurativa, sponsored by Incyte Corporation. Completed at 13 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-21.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Hidradenitis Suppurativa by Incyte Corporation — 3 open to participants now, 6 under way, 4 of them phase 3. Hidradenitis Suppurativa · Incyte Corporation.
Among the 12 studies in Hidradenitis Suppurativa by Incyte Corporation, this one is the 10th largest by enrollment, is one of 2 that started in 2018, is one of 5 in phase 2, and was the 2nd registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →3 of the 12 studies in Hidradenitis Suppurativa by Incyte Corporation are open now, in 12 countries. Recruiting first, the newest first:
Incyte Corporation · Sites in United States, Canada
Ages 12–17
Incyte Corporation · Sites in United States
Ages 12–75
Incyte Corporation · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
By country, each count listing its studies:
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 391 across the 12 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
2 of the studies in Hidradenitis Suppurativa by Incyte Corporation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06212999Phase 3Incyte CorporationA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12-26 |
| NCT07049575Incyte CorporationStudy to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa | 2026-12-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Hidradenitis Suppurativa by Incyte Corporation, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety of INCB054707 over an 8-week treatment period in men and women with moderate to severe hidradenitis suppurativa.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INCB054707 at the Cohort 1 dose or placebo.
Drug: INCB054707 · Drug: Placebo
INCB054707 at the Cohort 2 dose or placebo.
Drug: INCB054707 · Drug: Placebo
INCB054707 at the Cohort 3 dose or placebo.
Drug: INCB054707 · Drug: Placebo
INCB054707 tablet administered orally once daily at the protocol-defined dose.
Also known as: Povorcitinib
Placebo tablet administered orally once daily.
Number of Treatment-emergent Adverse Events (TEAEs)
TEAE is defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug. Grading was performed using guidance from the CTCAE v 4.03. A grade 3 and above would constitute as "severe".
Time frame: Up to 12 weeks
Apparent Oral Clearance of INCB054707
To determine the systemic exposure to INCB054707. Dependent upon the final compartmental model describing INCB054707.
Time frame: Predose Day 1, Week 4, and 8, Postdose Day1, week 2,4,6, and 8
Apparent Oral Volume of Distribution of INCB054707
To determine the systemic exposure to INCB054707. Dependent upon the final compartmental model describing INCB054707.
Time frame: Predose Day 1, Week 4, and 8, Postdose Day1, week 2,4,6, and 8
Proportion of Participants Achieving a Hidradenitis Suppurativa Clinical Response (HiSCR) at Each Visit
HiSCR defined as at least 50% reduction in abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to baseline.
Time frame: Weeks 1, 2, 4, 6, 8, Early Termination and Follow-up (Up to 3 months)
Proportion of Participants Achieving an AN Count of 0 to 2 at Each Visit
AN defined as abscess and inflammatory nodule count.
Time frame: Baseline,Weeks 1, 2, 4, 6, 8, Early Termination and Follow-up (Up to 3 months)
Mean Change From Baseline in the Hidradenitis Suppurativa Pain Numeric Rating Scale (HS Pain NRS) Scores at Each Visit
An 11-point scale used to assess the worst skin pain and the average skin pain due to HS. Skin pain ranges from 0 ("no skin pain") to 10 ("skin pain as bad as you can imagine").
Time frame: Baseline,Weeks 1, 2, 4, 6, 8, Early Termination and Follow-up (Up to 3 months)
Mean Change From Baseline in the Modified Sartorius Scale Score
The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other). For each area, points are awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated buy normal skin (yes-0 point; no-6 points). The total Sartorius Scale score is the sum of the 12 regional scores. Scale scores range from 0 to infinite, with larger scores representing higher severity of HS.
Time frame: From baseline up to week 8
Mean Change From Baseline in the Number of Draining Fistulas Count at Each Visit.
Defined as fistulas that drain serous or purulent fluid, either spontaneously or by gentle palpation.
Time frame: Baseline,Weeks 1, 2, 4, 6, 8 and Follow-up (Up to 3 months)
Proportion of Participants at Each Category of Hurley Stage
The Hurley classification is a static score and was originally designed for selection of the appropriate treatment modality in a certain body region. The assessor determines the Hurley stage in each affected anatomical region. If more than 1 stage is present in the same region, the worst stage in that region is documented. The participant will be assigned an overall Hurley stage classification corresponding to the stage of the worst involved anatomical region. The definition of each Hurley stage is as follows: Stage I : Abscess formation, single or multiple, without sinus tracts and cicatrization (scarring). Stage II : One or more widely separated recurrent abscesses with tract formation and cicatrization (scarring). Stage III : Multiple interconnected tracts and abscesses across the entire area, with diffuse or near diffuse involvement.
Time frame: Baseline and Week 8
Proportions of Participants in Each HS Patient Global Impression of Change (PGIC) Category During the Treatment Period
The HS-PGIC consists of 1 self-administered item that assesses change in the severity of skin in the HS area. The participant will answer the following: Since your last visit, your HS is: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse, or (7) very much worse.
Time frame: Up to 12 weeks
Actual Measurements in HS-PGIC at Each Visit
The HS-PGIC consists of 1 self-administered item that assesses change in the severity of skin in the HS area. The participant will answer the following: Since your last visit, your HS is: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse, or (7) very much worse.
Time frame: Up to 12 weeks
Proportion of Participants With Change From Baseline Hurley Stage
The Hurley classification is a static score and was originally designed for selection of the appropriate treatment modality in a certain body region. The assessor determines the Hurley stage in each affected anatomical region. If more than 1 stage is present in the same region, the worst stage in that region is documented. The participant will be assigned an overall Hurley stage classification corresponding to the stage of the worst involved anatomical region. The definition of each Hurley stage is as follows: Stage I : Abscess formation, single or multiple, without sinus tracts and cicatrization (scarring). Stage II : One or more widely separated recurrent abscesses with tract formation and cicatrization (scarring). Stage III : Multiple interconnected tracts and abscesses across the entire area, with diffuse or near diffuse involvement.
Time frame: Baseline and Week 8
The study was conducted at 9 different sites in Canada, 2 different sites in Germany and 1 site in Denmark
| Milestone | Placebo | INCB054707 at 30 mg | INCB054707 at 60 mg | INCB054707 at 90 mg |
|---|---|---|---|---|
| Started | 9 | 9 | 9 | 8 |
| Completed | 7 | 9 | 9 | 7 |
| Not completed | 2 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 | 1 |
To determine the systemic exposure to INCB054707. Dependent upon the final compartmental model describing INCB054707.
| L/hr | INCB54707 |
|---|---|
| Apparent Oral Clearance of INCB054707 | 5.27 ± 2.89 |
To determine the systemic exposure to INCB054707. Dependent upon the final compartmental model describing INCB054707.
| L | INCB54707 |
|---|---|
| Apparent Oral Volume of Distribution of INCB054707 | 239 ± 85.7 |
HiSCR defined as at least 50% reduction in abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to baseline.
| Participants | Placebo | INCB054707 at 30 mg | INCB054707 at 60 mg | INCB054707 at 90 mg |
|---|---|---|---|---|
| Week 1 — Yes | 1 | 1 | 4 | 2 |
| Week 1 — No | 6 | 8 | 5 | 5 |
| Week 2 — Yes | 1 | 6 | 5 | 4 |
| Week 2 — No | 6 | 3 | 4 | 4 |
| Week 4 — Yes | 3 | 5 | 5 | 5 |
| Week 4 — No | 4 | 4 | 4 | 3 |
| Week 6 — Yes | 3 | 3 | 6 | 6 |
| Week 6 — No | 4 | 6 | 3 | 2 |
| Week 8 — Yes | 4 | 5 | 5 | 7 |
| Week 8 — No | 3 | 4 | 4 | 1 |
| Follow Up — Yes | 3 | 3 | 1 | 4 |
| Follow Up — No | 4 | 6 | 8 | 3 |
| Early Termination — Yes | 0 | 0 | 0 | 0 |
| Early Termination — No | 1 | 0 | 0 | 0 |
AN defined as abscess and inflammatory nodule count.
| Participants | Placebo | INCB054707 at 30 mg | INCB054707 at 60 mg | INCB054707 at 90 mg |
|---|---|---|---|---|
| Baseline — Yes | 0 | 0 | 0 | 1 |
| Baseline — No | 9 | 9 | 9 | 7 |
| Week 1 — Yes | 0 | 0 | 2 | 2 |
| Week 1 — No | 7 | 9 | 7 | 5 |
| Week 2 — Yes | 0 | 3 | 5 | 4 |
| Week 2 — No | 7 | 6 | 4 | 4 |
| Week 4 — Yes | 2 | 3 | 6 | 5 |
| Week 4 — No | 5 | 6 | 3 | 3 |
| Week 6 — Yes | 3 | 2 | 5 | 5 |
| Week 6 — No | 4 | 7 | 4 | 3 |
| Week 8 — Yes | 4 | 4 | 4 | 5 |
| Week 8 — No | 3 | 5 | 5 | 3 |
| Follow Up — Yes | 1 | 3 | 0 | 4 |
| Follow Up — No | 6 | 6 | 9 | 3 |
| Early Termination — Yes | 0 | 0 | 0 | 0 |
| Early Termination — No | 1 | 0 | 0 | 0 |
An 11-point scale used to assess the worst skin pain and the average skin pain due to HS. Skin pain ranges from 0 ("no skin pain") to 10 ("skin pain as bad as you can imagine").
| Units on a scale | Placebo | INCB054707 at 30 mg | INCB054707 at 60 mg | INCB054707 at 90 mg |
|---|---|---|---|---|
| Mean change from Baseline to Week 1 | 0.2 ± 1.39 | -0.8 ± 1.13 | -0.3 ± 1.06 | -1.5 ± 1.04 |
| Mean change from Baseline to Week 2 | -0.1 ± 1.49 | -1.5 ± 1.18 | -1.1 ± 0.91 | -3.3 ± 3.06 |
| Mean change from Baseline to Week 4 | -0.3 ± 2.09 | -2.0 ± 2.02 | -1.4 ± 1.56 | -3.6 ± 3.30 |
| Mean change from Baseline to Week 6 | 0.0 ± 3.49 | -0.9 ± 0.90 | -2.0 ± 1.55 | -3.4 ± 3.05 |
| Mean change from Baseline to Week 8 | 0.3 ± 2.77 | -2.2 ± 2.18 | -1.4 ± 1.44 | -3.1 ± 3.28 |
| Mean change from Baseline to Follow Up | 2.6 ± 2.62 | -2.7 ± 2.20 | -0.8 ± 0.97 | -1.2 ± 1.91 |
The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other). For each area, points are awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated buy normal skin (yes-0 point; no-6 points). The total Sartorius Scale score is the sum of the 12 regional scores. Scale scores range from 0 to infinite, with larger scores representing higher severity of HS.
| Units on a scale | Placebo | INCB054707 at 30 mg | INCB054707 at 60 mg | INCB054707 at 90 mg |
|---|---|---|---|---|
| Mean Change From Baseline in the Modified Sartorius Scale Score | -36.4 ± 35.83 | -41.9 ± 36.84 | -59.2 ± 48.48 | -54.6 ± 55.42 |
Defined as fistulas that drain serous or purulent fluid, either spontaneously or by gentle palpation.
| Number of Fistulas | Placebo | INCB054707 at 30 mg | INCB054707 at 60 mg | INCB054707 at 90 mg |
|---|---|---|---|---|
| Week 1 | -0.1 ± 0.38 | -0.1 ± 1.27 | -0.8 ± 2.39 | -0.3 ± 0.49 |
| Week 2 | 0.0 ± 1.53 | -0.9 ± 1.05 | -2.1 ± 3.48 | -0.8 ± 2.19 |
| Week 4 | -0.9 ± 2.79 | -0.6 ± 1.01 | -2.0 ± 3.57 | -0.9 ± 2.53 |
| Week 6 | -1.3 ± 2.69 | -0.4 ± 1.74 | -2.1 ± 3.30 | -0.6 ± 2.72 |
| Week 8 | -1.0 ± 3.06 | -0.3 ± 1.66 | -2.0 ± 3.35 | -0.6 ± 3.85 |
| Follow Up | -0.4 ± 3.10 | 0.1 ± 1.69 | -2.2 ± 3.19 | -1.3 ± 3.86 |
The Hurley classification is a static score and was originally designed for selection of the appropriate treatment modality in a certain body region. The assessor determines the Hurley stage in each affected anatomical region. If more than 1 stage is present in the same region, the worst stage in that region is documented. The participant will be assigned an overall Hurley stage classification corresponding to the stage of the worst involved anatomical region. The definition of each Hurley stage is as follows: Stage I : Abscess formation, single or multiple, without sinus tracts and cicatrization (scarring). Stage II : One or more widely separated recurrent abscesses with tract formation and cicatrization (scarring). Stage III : Multiple interconnected tracts and abscesses across the entire area, with diffuse or near diffuse involvement.
| Participants | Placebo | INCB054707 at 30 mg | INCB054707 at 60 mg | INCB054707 at 90 mg |
|---|---|---|---|---|
| Baseline — Stage I | 0 | 0 | 0 | 0 |
| Baseline — Stage II | 4 | 9 | 5 | 7 |
| Baseline — Stage III | 5 | 0 | 4 | 1 |
| Baseline — No HS | 0 | 0 | 0 | 0 |
| Week 8 — Stage I | 1 | 3 | 3 | 0 |
| Week 8 — Stage II | 3 | 6 | 5 | 7 |
| Week 8 — Stage III | 3 | 0 | 0 | 0 |
| Week 8 — No HS | 0 | 0 | 1 | 1 |
The HS-PGIC consists of 1 self-administered item that assesses change in the severity of skin in the HS area. The participant will answer the following: Since your last visit, your HS is: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse, or (7) very much worse.
| Participants | Placebo | INCB054707 at 30 mg | INCB054707 at 60 mg | INCB054707 at 90 mg |
|---|---|---|---|---|
| Week 1 — 1 | 0 | 0 | 0 | 0 |
| Week 1 — 2 | 0 | 1 | 0 | 0 |
| Week 1 — 3 | 0 | 3 | 3 | 3 |
| Week 1 — 4 | 4 | 2 | 4 | 2 |
| Week 1 — 5 | 3 | 3 | 1 | 2 |
| Week 1 — 6 | 0 | 0 | 1 | 0 |
| Week 1 — 7 | 0 | 0 | 0 | 0 |
| Week 2 — 1 | 0 | 1 | 0 | 0 |
| Week 2 — 2 | 0 | 1 | 2 | 3 |
| Week 2 — 3 | 3 | 4 | 3 | 1 |
| Week 2 — 4 | 1 | 2 | 3 | 3 |
| Week 2 — 5 | 3 | 1 | 1 | 1 |
| Week 2 — 6 | 0 | 0 | 0 | 0 |
| Week 2 — 7 | 0 | 0 | 0 | 0 |
| Week 4 — 1 | 0 | 1 | 2 | 0 |
| Week 4 — 2 | 0 | 1 | 1 | 3 |
| Week 4 — 3 | 3 | 2 | 1 | 1 |
| Week 4 — 4 | 2 | 2 | 2 | 2 |
| Week 4 — 5 | 2 | 1 | 2 | 2 |
| Week 4 — 6 | 0 | 1 | 1 | 0 |
| Week 4 — 7 | 0 | 1 | 0 | 0 |
| Week 6 — 1 | 0 | 0 | 1 | 0 |
| Week 6 — 2 | 1 | 1 | 1 | 2 |
| Week 6 — 3 | 3 | 2 | 3 | 2 |
| Week 6 — 4 | 1 | 4 | 1 | 4 |
| Week 6 — 5 | 2 | 1 | 3 | 0 |
| Week 6 — 6 | 0 | 1 | 0 | 0 |
| Week 6 — 7 | 0 | 0 | 0 | 0 |
| Week 8 — 1 | 0 | 0 | 0 | 1 |
| Week 8 — 2 | 0 | 3 | 1 | 0 |
| Week 8 — 3 | 1 | 1 | 3 | 1 |
| Week 8 — 4 | 5 | 3 | 4 | 2 |
| Week 8 — 5 | 1 | 1 | 1 | 3 |
| Week 8 — 6 | 0 | 1 | 0 | 1 |
| Week 8 — 7 | 0 | 0 | 0 | 0 |
| Early Termination — 1 | 0 | 0 | 0 | 0 |
| Early Termination — 2 | 0 | 0 | 0 | 0 |
| Early Termination — 3 | 0 | 0 | 0 | 0 |
| Early Termination — 4 | 1 | 0 | 0 | 0 |
| Early Termination — 5 | 0 | 0 | 0 | 0 |
| Early Termination — 6 | 0 | 0 | 0 | 0 |
| Early Termination — 7 | 0 | 0 | 0 | 0 |
| Follow Up — 1 | 0 | 0 | 0 | 0 |
| Follow Up — 2 | 0 | 1 | 0 | 0 |
| Follow Up — 3 | 1 | 1 | 0 | 0 |
| Follow Up — 4 | 1 | 2 | 2 | 1 |
| Follow Up — 5 | 3 | 2 | 2 | 3 |
| Follow Up — 6 | 2 | 3 | 4 | 0 |
| Follow Up — 7 | 0 | 0 | 1 | 3 |
The HS-PGIC consists of 1 self-administered item that assesses change in the severity of skin in the HS area. The participant will answer the following: Since your last visit, your HS is: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse, or (7) very much worse.
| Participants | Placebo | INCB054707 at 30 mg | INCB054707 at 60 mg | INCB054707 at 90 mg |
|---|---|---|---|---|
| Week 1 — 1 | 0 | 0 | 0 | 0 |
| Week 1 — 2 | 0 | 1 | 0 | 0 |
| Week 1 — 3 | 0 | 3 | 3 | 3 |
| Week 1 — 4 | 4 | 2 | 4 | 2 |
| Week 1 — 5 | 3 | 3 | 1 | 2 |
| Week 1 — 6 | 0 | 0 | 1 | 0 |
| Week 1 — 7 | 0 | 0 | 0 | 0 |
| Week 2 — 1 | 0 | 1 | 0 | 0 |
| Week 2 — 2 | 0 | 1 | 2 | 3 |
| Week 2 — 3 | 3 | 4 | 3 | 1 |
| Week 2 — 4 | 1 | 2 | 3 | 3 |
| Week 2 — 5 | 3 | 1 | 1 | 1 |
| Week 2 — 6 | 0 | 0 | 0 | 0 |
| Week 2 — 7 | 0 | 0 | 0 | 0 |
| Week 4 — 1 | 0 | 1 | 2 | 0 |
| Week 4 — 2 | 0 | 1 | 1 | 3 |
| Week 4 — 3 | 3 | 2 | 1 | 1 |
| Week 4 — 4 | 2 | 2 | 2 | 2 |
| Week 4 — 5 | 2 | 1 | 2 | 2 |
| Week 4 — 6 | 0 | 1 | 1 | 0 |
| Week 4 — 7 | 0 | 1 | 0 | 0 |
| Week 6 — 1 | 0 | 0 | 1 | 0 |
| Week 6 — 2 | 1 | 1 | 1 | 2 |
| Week 6 — 3 | 3 | 2 | 3 | 2 |
| Week 6 — 4 | 1 | 4 | 1 | 4 |
| Week 6 — 5 | 2 | 1 | 3 | 0 |
| Week 6 — 6 | 0 | 1 | 0 | 0 |
| Week 6 — 7 | 0 | 0 | 0 | 0 |
| Week 8 — 1 | 0 | 0 | 0 | 1 |
| Week 8 — 2 | 0 | 3 | 1 | 0 |
| Week 8 — 3 | 1 | 1 | 3 | 1 |
| Week 8 — 4 | 5 | 3 | 4 | 2 |
| Week 8 — 5 | 1 | 1 | 1 | 3 |
| Week 8 — 6 | 0 | 1 | 0 | 1 |
| Week 8 — 7 | 0 | 0 | 0 | 0 |
| Early Termination — 1 | 0 | 0 | 0 | 0 |
| Early Termination — 2 | 0 | 0 | 0 | 0 |
| Early Termination — 3 | 0 | 0 | 0 | 0 |
| Early Termination — 4 | 1 | 0 | 0 | 0 |
| Early Termination — 5 | 0 | 0 | 0 | 0 |
| Early Termination — 6 | 0 | 0 | 0 | 0 |
| Early Termination — 7 | 0 | 0 | 0 | 0 |
| Follow Up — 1 | 0 | 0 | 0 | 0 |
| Follow Up — 2 | 0 | 1 | 0 | 0 |
| Follow Up — 3 | 1 | 1 | 0 | 0 |
| Follow Up — 4 | 1 | 2 | 2 | 1 |
| Follow Up — 5 | 3 | 2 | 2 | 3 |
| Follow Up — 6 | 2 | 3 | 4 | 0 |
| Follow Up — 7 | 0 | 0 | 1 | 3 |
The Hurley classification is a static score and was originally designed for selection of the appropriate treatment modality in a certain body region. The assessor determines the Hurley stage in each affected anatomical region. If more than 1 stage is present in the same region, the worst stage in that region is documented. The participant will be assigned an overall Hurley stage classification corresponding to the stage of the worst involved anatomical region. The definition of each Hurley stage is as follows: Stage I : Abscess formation, single or multiple, without sinus tracts and cicatrization (scarring). Stage II : One or more widely separated recurrent abscesses with tract formation and cicatrization (scarring). Stage III : Multiple interconnected tracts and abscesses across the entire area, with diffuse or near diffuse involvement.
| Participants | Placebo | INCB054707 at 30 mg | INCB054707 at 60 mg | INCB054707 at 90 mg |
|---|---|---|---|---|
| Baseline — Stage I | 0 | 0 | 0 | 0 |
| Baseline — Stage II | 4 | 9 | 5 | 7 |
| Baseline — Stage III | 5 | 0 | 4 | 1 |
| Baseline — No HS | 0 | 0 | 0 | 0 |
| Baseline — Missing | 0 | 0 | 0 | 0 |
| Week 8 — Stage I | 1 | 3 | 3 | 0 |
| Week 8 — Stage II | 3 | 6 | 5 | 7 |
| Week 8 — Stage III | 3 | 0 | 0 | 0 |
| Week 8 — No HS | 0 | 0 | 1 | 1 |
| Week 8 — Missing | 2 | 0 | 0 | 0 |
TEAE is defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug. Grading was performed using guidance from the CTCAE v 4.03. A grade 3 and above would constitute as "severe".
| Participants | Placebo | INCB054707 at 30 mg | INCB054707 at 60 mg | INCB054707 at 90 mg |
|---|---|---|---|---|
| Grade 1 | 2 | 6 | 4 | 1 |
| Grade 2 | 2 | 2 | 2 | 3 |
| Grade 3 | 0 | 0 | 0 | 3 |
| Grade 4 | 0 | 0 | 0 | 0 |
Collected over up to 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/9 (0%) | 0/9 (0%) | 4/9 (44.4%) |
| INCB054707 at 30 mg | 0/9 (0%) | 0/9 (0%) | 8/9 (88.9%) |
| INCB054707 at 60 mg | 0/9 (0%) | 0/9 (0%) | 6/9 (66.7%) |
| INCB054707 at 90 mg | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Total | 0/35 (0%) | 0/35 (0%) | 25/35 (71.4%) |
| Event | Placebo | INCB054707 at 30 mg | INCB054707 at 60 mg | INCB054707 at 90 mg | Total |
|---|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 0/9 | 0/9 | 0/9 | 4/8 | 4/35 |
| FatigueGeneral disorders | 1/9 | 1/9 | 2/9 | 3/8 | 7/35 |
| HeadacheNervous system disorders | 2/9 | 0/9 | 2/9 | 2/8 | 6/35 |
| DiarrhoeaGastrointestinal disorders | 2/9 | 1/9 | 0/9 | 0/8 | 3/35 |
| FolliculitisInfections and infestations | 1/9 | 2/9 | 1/9 | 0/8 | 4/35 |
| GastroenteritisInfections and infestations | 0/9 | 0/9 | 2/9 | 0/8 | 2/35 |
| NasopharyngitisInfections and infestations | 1/9 | 1/9 | 2/9 | 0/8 | 4/35 |
| AcneSkin and subcutaneous tissue disorders | 0/9 | 0/9 | 0/9 | 1/8 | 1/35 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/9 | 1/9 | 0/9 | 1/8 | 2/35 |
| Chest painGeneral disorders | 0/9 | 0/9 | 0/9 | 1/8 | 1/35 |
| Age, Continuous(years) | Placebo | INCB054707 at 30 mg | INCB054707 at 60 mg | INCB054707 at 90 mg | Total |
|---|---|---|---|---|---|
| Mean | 40.3 ± 16.70 | 41.0 ± 11.53 | 42.2 ± 11.96 | 42.8 ± 14.62 | 41.5 ± 13.25 |
| Sex: Female, Male(Participants) | Placebo | INCB054707 at 30 mg | INCB054707 at 60 mg | INCB054707 at 90 mg | Total |
|---|---|---|---|---|---|
| Female | 8 | 7 | 8 | 5 | 28 |
| Male | 1 | 2 | 1 | 3 | 7 |
| Race/Ethnicity, Customized(Participants) | Placebo | INCB054707 at 30 mg | INCB054707 at 60 mg | INCB054707 at 90 mg | Total |
|---|---|---|---|---|---|
| White/Caucasian | 8 | 7 | 9 | 7 | 31 |
| Black/African-American | 0 | 0 | 0 | 1 | 1 |
| American-Indian/Alaska Native | 0 | 2 | 0 | 0 | 2 |
| Other | 1 | 0 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Placebo | INCB054707 at 30 mg | INCB054707 at 60 mg | INCB054707 at 90 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 0 | 1 |
| Not Hispanic or Latino | 9 | 7 | 9 | 8 | 33 |
| Not Reported | 0 | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2018 to primary completion in Aug 2019, 9 months.
Results were first posted in Sep 2020, 1 year 1 month after primary completion.
Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 9 months is below that.
Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Povorcitinib